

# Sesquiterpenes from Myrrh and their ICAM-1 Inhibitory Activity *in vitro*

Katrin Kuck <sup>1</sup>, Guido Jürgenliemk <sup>1</sup>, Bartosz Lipowicz <sup>2</sup> and Jörg Heilmann <sup>1,\*</sup>

<sup>1</sup> Institute of Pharmaceutical Biology, Universitätsstr. 31, Regensburg D-93053, Germany

<sup>2</sup> Repha GmbH Biologische Arzneimittel, Alt-Godshorn 87, Langenhagen D-30855, Germany

\* Correspondence: joerg.heilmann@chemie.uni-regensburg.de

## Supplementary Material

**Table S1.** <sup>1</sup>H-NMR data of compound **8** (400 MHz; CDCl<sub>3</sub>) and **10–12** (600 MHz; CDCl<sub>3</sub>) (δ in ppm, *J* in Hz; s singlet, d doublet, br broad, m multiplet).

no.	<b>8</b>	<b>10</b>	<b>11</b>	<b>12</b>
1	5.53 (1H, d, 8.7)	1.25 (1H, m) 1.58 (1H, m)	6.87 (1H, d, 9.9)	
2	5.76 (1H, dd, 5.7, 8.7)	1.64 (2H, m)	6.37 (1H, d, 9.9)	2.45 (1H, ddd, 3.6, 4.1, 15.1) 2.73 (1H, ddd, 6.0, 15.1, 15.1)
3	5.74 <sup>1</sup> (1H, m)	1.97 (1H, ddd, 6.7, 12.5, 12.5) 2.37 (1H, ddd, 12.5)		1.93 (1H, ddd, 5.2, 14.5, 14.9) 2.03 (1H, ddd, 2.8, 6.0, 13.3)
5	2.32 (1H, m)	1.84 (1H, dd, 3.3, 13.2)		2.89 (1H, s)
6	2.45 (1H, dd, 13.0, 13.0) 2.87 (1H, dd, 3.4, 13.0)	2.43 (1H, dd, 13.2, 13.2) 2.63 (1H, dd, 3.3, 13.2)		
9	1.82 (1H, d, 13.8) 2.28 (1H, d, 13.8)	1.56 (1H, d, 13.8) 2.25 (1H, d, 13.8)	2.94 (1H, d, 16.9) 3.00 (1H, d, 16.9)	3.03 (1H, d, 17.9) 2.95 (1H, d, 17.9)
12			7.17 (1H, s)	7.12 (1H, s)
13	1.84 (3H, brs)	1.83 (3H, brs)	2.27 (3H, brs)	2.20 (3H, s)
14	1.13 (3H, s)	1.03 (3H, s)	1.39 (3H, s)	1.27 (3H, s)
15	1.89 (1H, s)	4.60 (1H, brs) 4.87 (1H, brs)	2.19 (3H, s)	1.73 (3H, s)


<sup>1</sup> overlapped signal

**Table S2.** <sup>1</sup>H NMR data of compound **13**, **15** and **16** (600 MHz; CDCl<sub>3</sub>) (δ in ppm, *J* in Hz; s singlet, d doublet, t triplet, br broad).

no.	<b>13</b>	<b>15</b>	<b>16</b>
1	5.73 (1H, dd, 10.8, 17.6)	4.68 (1H, d, 12.9)	4.90 (1H, d, 12.9)
2	4.97 (1H, brd, 17.6) 5.00 (1H, brd, 11.0)	6.17 (1H, d, 12.9)	6.45 (1H, d, 12.9)
3	4.73 (1H, brs) 4.99 (1H, brs)	4.74 (1H, brs) 5.01 (1H, brs)	4.68 (1H, brs) 4.80 (1H, brs)
5	2.05 (1H, dd, 4.1, 14.0)	2.00 (1H, dd, 4.1, 13.5)	2.47 (1H, brd, 6.6)
6	2.55 (1H, brt, 14.0, 14.0) 2.68 (1H, dd, 4.1, 14.0)	2.53 (1H, dd, 14.0, 14.0) 2.67 (1H, dd, 3.9, 14.0)	2.69 (1H, brd, 14.9) 2.72 (1H, dd, 7.1, 14.9)
8	4.83 (1H, dd, 6.2, 12.0)	4.82 (1H, dd, 6.2, 12.0)	4.93 (1H, dd, 6.6, 11.6)
9	1.34 (1H, t, 12.0) 2.21 (1H, dd, 6.2, 12.0)	1.31 (1H, dd, 12.1, 12.1) 2.26 (1H, dd, 6.2, 12.1)	1.68 (1H, dd, 12.1, 12.1) 2.20 (1H, dd, 6.6, 12.5)
13	1.83 (3H, t, 1.4, 1.4)	1.82 (3H, brs)	1.81 (3H, brs)
14	1.17 (3H, s)	1.15 (3H, s)	1.05 (3H, s)
15	1.77 (1H, s)	1.79 (3H, s)	1.70 (3H, s)
1'-Me		3.50 (3H, s)	3.55 (3H, s)

**Table S3.**  $^{13}\text{C}$ -NMR data of compound **8** (100 MHz;  $\text{CDCl}_3$ ) and **10-16** (150 MHz;  $\text{CDCl}_3$ ) ( $\delta$  in ppm).

no.	8	10	11	12	13	15	16
1	137.0	41.3	153.0	210.9	146.5	112.8	111.5
2	122.5	22.3	126.9	34.7	111.8	145.9	147.4
3	120.7	36.1	186.4	38.8	113.9	113.9	113.8
4	136.2	148.5	137.6	70.2	144.9	145.1	147.3
5	48.3	51.7	150.6	62.1	52.9	54.0	51.1
6	23.1	24.5	186.8	195.4	28.4	28.3	28.6
7	160.4	160.7	121.5	119.3	161.9	162.0	161.8
8	103.5	103.3	163.6	165.8	77.9	77.8	78.3
9	48.0	51.3	36.6	35.6	45.7	47.0	40.4
10	35.8	36.7	42.4	51.1	40.9	38.0	37.9
11	122.4	122.3	119.6	119.0	120.1	120.0	120.8
12	172.1	171.9	140.7	140.1	174.9	174.8	174.7
13	8.3	8.2	9.0	8.9	8.2	8.2	8.3
14	15.3	16.6	24.9	20.3	17.0	18.1	28.9
15	20.2	106.9	12.2	23.8	24.7	25.0	25.4
1'-Me						56.1	56.4



**Figure S1.** Influence of the ethanolic extract, HEP fraction, compound **7** and FUR on viability of HMEC-1 cells (MTT assay). The test was performed with pure medium (u.c.), the highest DMSO concentration used in test solutions (0.15%, *v/v*) and substance concentrations between 25–100  $\mu\text{M}$ . Data are presented as mean  $\pm$  SD ( $n = 3$ ). All viability values are situated between 95–100%.




Figure S2. CD-spectra of compounds 2–16 in a range of 190–300 nm.